HUTCHMED to Present Promising Cancer Therapy Data at ASCO 2025

HUTCHMED (China) Limited has announced its participation in the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 – June 3, 2025, in Chicago. The company will unveil new data on its cancer therapies, including savolitinib, ranosidenib, fruquintinib, and surufatinib.

Key Highlights from HUTCHMED’s Upcoming Presentations

Among the notable findings, results from the Phase III SACHI study will show that savolitinib, when combined with osimertinib, improves progression-free survival in patients with advanced non-small cell lung cancer (NSCLC) with MET amplification. Furthermore, presentations will cover various studies that highlight the efficacy and safety of HUTCHMED’s drug candidates. Ranoseidenib shows favorable tolerance in patients with solid tumors, while fruquintinib has promising outcomes in treating advanced endometrial and colorectal cancers. Safety analyses indicate that fruquintinib maintains a manageable side effect profile across different patient age groups, with continuous treatment suggesting better patient outcomes.

Strengths of HUTCHMED’s Research and Development

• The upcoming ASCO presentations reflect HUTCHMED’s commitment to advancing oncology research and development.
• The SACHI study’s interim analysis shows promising efficacy for the savolitinib and osimertinib combination, supporting further regulatory applications.
• Data from ranosidenib highlight early efficacy and tolerability for patients with IDH mutations, indicating potential for impactful treatments.
• Robust data from fruquintinib studies suggest significant clinical outcomes, enhancing HUTCHMED’s standing in oncology.

Challenges and Considerations

• Concerns about ranosidenib’s effectiveness were raised, as the objective response rate (ORR) was only 7.1% in lower-grade glioma patients, indicating limited impact.
• Safety concerns emerged regarding fruquintinib, which showed 23.94% treatment-emergent adverse events (TEAEs) at Grade 3 or above in monotherapy and 26.06% in combination therapy.
• The reliance on positive outcomes from multiple studies introduces uncertainty surrounding future regulatory approvals and market acceptance of HUTCHMED’s therapies.

Frequently Asked Questions

What is the significance of HUTCHMED’s upcoming data at ASCO 2025?

The presented data will focus on the efficacy of critical compounds like savolitinib and ranosidenib in cancer treatment.

When and where will HUTCHMED present its findings?

HUTCHMED will showcase its research at the ASCO Annual Meeting in Chicago from May 30 to June 3, 2025.

What were the promising findings from the SACHI Phase III study?

The SACHI study indicated improved progression-free survival for savolitinib combined with osimertinib in NSCLC patients.

How effective was ranosidenib in the Phase I study?

Ranosidenib was well-tolerated and demonstrated a 7.1% objective response rate in lower-grade glioma patients, alongside a 100% disease control rate.

What does the safety profile of fruquintinib look like in colorectal cancer treatment?

Fruquintinib presents a manageable safety profile, exhibiting tolerability in both monotherapy and combination therapy for colorectal cancer patients.

$HCM Hedge Fund Activity

Recent reports indicated that 19 institutional investors increased their stakes in $HCM, while 44 reduced their holdings in the latest quarter.

Some significant changes include:

• UBS GROUP AG removed 161,163 shares (-42.7%) from their portfolio in Q1 2025, equating to approximately $2,423,891.
• JANE STREET GROUP, LLC added 124,771 shares (+128.0%) in Q1 2025, valued at around $1,876,555.
• ALLIANZ ASSET MANAGEMENT GMBH decreased its holdings by 117,521 shares (-10.5%) in Q1 2025, valued at an estimated $1,767,515.
• MILLENNIUM MANAGEMENT LLC cut 99,058 shares (-47.3%) from their portfolio in Q1 2025, for about $1,489,832.
• SCHRODER INVESTMENT MANAGEMENT GROUP added 74,572 shares (+2.7%) in Q1 2025, worth approximately $1,121,562.
• XY CAPITAL LTD increased its stake by 66,460 shares (+142.4%) in Q1 2025, amounting to about $999,558.
• BLACKROCK, INC. added 57,707 shares (+369.9%) in Q1 2025, valued at around $867,913.

Full Release

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“

HUTCHMED

”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds developed by HUTCHMED—including savolitinib, ranosidenib, fruquintinib, and surufatinib—will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting from May 30 – June 3, 2025, in Chicago, USA.

Results from the SACHI China Phase III study evaluating savolitinib alongside osimertinib in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive NSCLC, specifically with MET amplification after prior disease progression on EGFR inhibitors, will be disclosed in a late-breaking oral presentation. The SACHI study met its primary endpoint of progression-free survival (PFS) in an interim analysis, supporting the New Drug Application (NDA) for this oral-only treatment, which has been accepted and granted priority review in China.

Further data with additional analyses from the SAVANNAH Phase II study on savolitinib and osimertinib in NSCLC patients harboring EGFR mutation with MET amplification or overexpression after progression on osimertinib will demonstrate potentially improved efficacy outcomes compared to savolitinib plus placebo. This combination therapy shows promising central nervous system (CNS) activity, evidenced by reduced CNS progression and fewer new CNS lesions.

Results will additionally be shared from the dose-escalation phase of the Phase I study of ranosidenib (HMPL-306), a novel oral dual-inhibitor of the IDH 1 and IDH 2 enzymes, being investigated in patients with locally advanced or metastatic solid tumors with IDH mutations. Findings indicate the compound is well-tolerated, demonstrating target inhibition and durable responses, especially among lower-grade glioma patients (N=14), with an objective response rate (ORR) of 7.1% and a notable disease control rate.